U.S. markets closed
  • S&P Futures

    4,360.50
    -43.25 (-0.98%)
     
  • Dow Futures

    34,002.00
    -251.00 (-0.73%)
     
  • Nasdaq Futures

    14,318.50
    -182.50 (-1.26%)
     
  • Russell 2000 Futures

    2,007.90
    -23.80 (-1.17%)
     
  • Crude Oil

    83.64
    +0.33 (+0.40%)
     
  • Gold

    1,842.50
    +0.80 (+0.04%)
     
  • Silver

    23.84
    +0.05 (+0.19%)
     
  • EUR/USD

    1.1325
    -0.0005 (-0.05%)
     
  • 10-Yr Bond

    1.7350
    -0.0120 (-0.69%)
     
  • Vix

    29.90
    +1.05 (+3.64%)
     
  • GBP/USD

    1.3481
    -0.0009 (-0.07%)
     
  • USD/JPY

    113.9060
    -0.0540 (-0.05%)
     
  • BTC-USD

    36,087.52
    +109.62 (+0.30%)
     
  • CMC Crypto 200

    821.53
    +10.93 (+1.35%)
     
  • FTSE 100

    7,297.15
    -196.98 (-2.63%)
     
  • Nikkei 225

    27,113.13
    -475.24 (-1.72%)
     

Unicycive Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • UNCY

LOS ALTOS, Calif., Sept. 7, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.

Unicycive (PRNewsfoto/Unicycive Therapeutics Inc.)
Unicycive (PRNewsfoto/Unicycive Therapeutics Inc.)

A link to the webcast will be available on September 13, 2021 and may be accessed on the Unicycive website under the Investors section:Events and Presentations. An archive of the webcast will be available for three months.

About Unicycive

Unicycive is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit www.unicycive.com.

Contacts:

Remy Bernarda
ir@unicycive.com
(650) 900-5470

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/unicycive-therapeutics-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301369986.html

SOURCE Unicycive Therapeutics Inc.